Shimon Eckhouse brings Epitomee Medical to TASE

Shimon Eckhouse  credit: Eyal Izhar
Shimon Eckhouse credit: Eyal Izhar

The flotation is Eckhouse's second in six months. Epitomee has developed a pill for treating obesity and drug delivery.

Despite the cooling of the primary market in Tel Aviv in the past few months (following a record year in which more than 100 new companies were floated on the Tel Aviv Stock Exchange), there are those who are still welcomed with open arms, and one of them is Dr. Shimon Eckhouse, who at the end of last week floated a second company within just over six months, after the IPO by SofWave in May. Eckhouse founded aesthetic medicine companies Syneron and Lumenis, which were floated on Wall Street and sold for huge sums, and was also a partner in the founding of heart valve company Ventor, which was sold for over $300 million.

The latest public company from the Eckhouse stable is Epitomee, developer of an ingestible pill for treating obesity and for delivering drugs to the stomach. As first reported by "Globes", the company sought to raise NIS 155 million at a pre-money valuation of NIS 620 million. In the end, it raised NIS 162 million at a valuation of NIS 632 million. The offering was led by Leumi Partners Underwriting and Barak Capital.

At the same time as the offering, global food company Nestlé, an investor in the company and its marketing partner, converted a $7 million loan to equity, bringing the total amount raised in the offering to NIS 187 million.

The pill developed by Epitomee expands in the stomach, creating a sensation of fullness. The pill is made of material defined as a food ingredient, and it disintegrates within a few hours, enough time to eat a reasonable meal and swallow another satisfying pill. The company's CEO is Dr. Dan Hashimshony, one of the founders of Dune Medical Devices.

In August 2020, Epitomee received external confirmation of the validity of its technology and the product's commercial potential when it signed an exclusive marketing agreement for its lead product with Nestlé Health Science. Epitomee will be entitled to receive $115 million in advance and milestone payments, as well as royalties on the product. An advance of $10 million has already been paid under the agreement.

In its last fund-raising round as a privately held company, led by Eckhouse in 2019, $8 million were invested in the company at a valuation of just $27 million.

The main shareholders in Epitomee are Eckhouse (28%), Chinese fund Star Concept (9.3%), Oriella, a company indirectly held by Rodney Hodges (7.7%), and companies owned by Idan Ofer and Udi Angel (altogether 16.5%).

According to its prospectus, Epitomee will start commercial production and sales in early 2023. Its product has the CE mark and the company has filed for approval from the US Food and Drug Administration. The product will cost $100-200 for a month's worth of pills for use several times daily. Epitomee has additional products, for treating diabetes, prediabetes, and other indications.

Epitomee was founded as Tulip Medical in 2005 by Eckhouse and Doron Marco. It has accumulated losses of some $30 million.

Published by Globes, Israel business news - en.globes.co.il - on December 13, 2021.

© Copyright of Globes Publisher Itonut (1983) Ltd., 2021.

Shimon Eckhouse  credit: Eyal Izhar
Shimon Eckhouse credit: Eyal Izhar
Inflation  credit: Tali Bogdanovsky Unexpectedly low February CPI reading cuts inflation

While inflation in Israel in the 12 months to the end of February 2025 is lower than forecast, housing prices continue to rise.

Yitzhak Tshuva credit: Gidon Levy and Tali Bogdanovsky Competition Authority allows Delek takeover of Isracard

The Competition Authority is considered the easier of the two regulatory hurdles that the deal must overcome, the other being the Supervisor of Banks.

David Amsalem  credit  Noam Moskowitz, Knesset Spokesperson's Office Rafael to pay state NIS 444m dividend

The minister in charge of the Government Companies Authority, David Amsalem, has approved the payment by the defense company.

Barak MX air defense system  credit: IAI IAI profit jumps 55%

Israel Aerospace Industries posted a net profit of $493 million for 2024, and ended the year with an all-time high orders backlog of $25 billion.

A TSG system in tactical use  credit: PR TSG signs cooperation agreement with US defense co

The agreement includes the integration of TSG's advanced technologies into sensor-based defense systems, which will be integrated into the operational systems of US defense units.

Bria CEO Yair Adato credit: Kseniia Poliak Israeli visual generative AI co Bria raises $40m

Bria’s Visual Generative AI platform empowers businesses to create predictable, controllable, and on-brand content that aligns with their visual language.

Amnon Shashua and Aviram Ziv credit: Eyal Izhar OrCam stymied by investor dispute with Shashua

Demands by institutional investors are blocking the visual and hearing impairment device developer's recovery plan.

Work on the Green Line credit: Bar Lavi Egged wins tender to operate TA light rail Purple, Green Lines

NTA awarded the tender to Egged, which already operates the Red Line, despite government ministry opposition to one operator for the entire network.

Gabi Seroussi illustration: Gil Gibli Board chooses Seroussi as IAI chair as Erdan freezes candidacy

Israel Aerospace Industries board chose Gabi Seroussi as chair even though he did not to go through the preliminary process of the Government Companies Authority appointments review committee.

Bavli Park penthouse credit: Eyal Tagar Tel Aviv Park Bavli penthouse sells for NIS 43m

A 44th floor penthouse in one of the two towers in businessman Yitzhak Tshuva's Park Bavli project has been bought by an Israeli businessperson.

El Al aircraft  credit: Yoav Yaari El Al pilots receive nearly NIS 250,000 bonus each

Thanks to the agreements signed with the unions in 2018, El Al's employees as well as senior management share in last year's success.

Pentera CEO Amitai Ratzon credit: Eyal Izhar Israeli security validation co Pentera raises $60m

Pentera's platform enables security teams to analyze complete attack paths, identify root causes, and prioritize remediation for effective risk reduction.

Tel Aviv credit: Shutterstock Supply of unsold new homes hits record

Israel's real estate market is sliding into recession with 78,000 unsold new apartments in January, the Central Bureau of Statistics reports.

D&B chairman Doron Cohen and Meitar partner Dan Geva Meitar reclaims title of Israel's biggest law firm

Meitar has first place with 537 lawyers, followed by Herzog Fox Neeman with 512 lawyers, according to the latest Dun's 100 rankings.

First International Bank of Israel CEO Eli Cohen  credit: Eyal Toueg First Int'l posts top return on equity

First International Bank of Israel's return on equity in 2024 was 19%, the highest among Israel's banks.

Dina Ben Tal Ganancia  credit: Guy Kushi & Yariv Fein El Al almost quintuples profit

The airline posted a net profit of $545 million for 2024, 4.7 times the profit in 2023, and an all-time high.

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018